DEV

You are viewing our development site. Please share feedback with support@dosevault.ai or on our Discord server. See what is new in the changelog.

DOSEVAULT
MetabolicClinical Evidence: Moderate

Retatrutide

Retatrutide (LY3437943) is a long-acting triple agonist developed by Eli Lilly that simultaneously activates GLP-1, GIP, and glucagon receptors. GLP-1 receptor activation suppresses appetite and slows gastric emptying; GIP receptor activation potentiates insulin secretion and may enhance GLP-1-mediated weight loss; glucagon receptor activation increases energy expenditure and promotes hepatic fat oxidation, contributing to observed hepatic steatosis reduction. The combined incretin and glucagon signaling drove greater weight loss than single- or dual-agonist agents in Phase 2 data. The Phase 3 TRIUMPH program is ongoing; not FDA-approved as of 2026.

Molecular Profile
linear
39 AA Sequence
Evidence grade (Moderate): Small clinical studies or well-designed non-RCT human research. This grade reflects the overall quality of available research on this compound and does not constitute a clinical recommendation.
CAS
2381089-83-2
Formula
Modified Peptide
Chain length
39 aa
Sequence
triple GIP/GLP-1/glucagon 39-amino-acid analog
Onset and duration

Appetite suppression often within the first days; weight loss accrues over weeks to months alongside titration.

Storage and reconstitution

Store the lyophilized powder refrigerated (2 to 8 C), or frozen for long-term storage, protected from light. After reconstitution with bacteriostatic water, keep refrigerated and use within about 4 weeks.

Clinical Evidence

What the literature says

Scientific Overview

Retatrutide is an investigational triple agonist developed by Eli Lilly. It mimics GLP-1, GIP, and glucagon, leading to significant improvements in weight, glycemic control, and liver health.

Pharmacokinetics

Half-life (t½)
6.0 d
Approximate plasma half-life
Routes
Subcutaneous
Plasma decay
100%~3%@ 5× t½

t½ 6.0 d · ~3% remaining at 30 d

Citations (7)

  1. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 TrialPubMed
  2. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USAPubMed
  3. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trialPubMed
  4. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trialReview
  5. Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trialsReview
  6. TRIUMPH phase 3 program design for retatrutidePubMed
  7. TRIUMPH-1: A Study of Retatrutide (LY3437943) in Participants With ObesityReview

Last reviewed: 2026-06-14

Research Guide

How users approach this compound

The following reflects patterns observed in research literature and community protocols. This is not medical advice and does not constitute a clinical recommendation.

Typical Dose Range Observed

2–12 mg
subcutaneous injection, weekly

Research Protocols

Common Dosages

Triple Agonist protocol

2 mg -> 12 mg
Weekly

“Newest generations of metabolic therapy”

Dosages listed are common research protocols found in peer-reviewed literature and clinical trials. Individual results and requirements may vary significantly in a research context.

Reported Uses

  • Studied for investigational weight management in adults with obesity (Phase 3 TRIUMPH program)
  • Investigated for type 2 diabetes glycemic control via triple incretin receptor agonism
  • Investigated for MASLD / hepatic steatosis reduction based on Phase 2a liver data

Key Research Benefits

  • Unrivaled weight loss (up to 24%+)
  • Reverses liver fat (80%+ reduction)
  • Normalizes blood sugar
  • Reduces visceral fat

Potential Side Effects

Nausea
Diarrhea
Vomiting
Increased heart rate (mild)

Considerations and Cautions

  • Personal or family history of medullary thyroid carcinoma (boxed-warning class effect shared with GLP-1 receptor agonists)
  • Personal or family history of Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
  • Pregnancy
  • History of pancreatitis
  • Severe gastroparesis
  • Investigational compound: safety profile not fully characterized; use outside clinical trials carries additional unknown risks

Labs to monitor

Educational context only, not a testing mandate. Any bloodwork decisions belong with your clinician.

  • HbA1c: Primary glycemic efficacy marker for incretin therapy.
  • Fasting glucose: Tracks glycemic response and hypoglycemia risk when combined with other agents.
  • Lipid panel / ApoB: Incretin therapy commonly improves atherogenic lipids alongside weight loss.

Dose Calculator

Peptide Reconstitution Calculator

mg

Total amount of peptide in the vial.

mL

Volume of water used to mix.

mcg

Draw to this mark

10 Units

or 0.10 mL on a U-100 syringe

Concentration:2.50 mg/mL
Peptide per Unit:25.00 mcg/unit
*Always double-check your calculations. This tool is for educational purposes only.

Quick Explainer

Retatrutide is the next generation of weight loss peptides. As a triple-hormone-receptor agonist, it targets GLP-1, GIP, and glucagon receptors simultaneously, making it potentially the most powerful metabolic tool ever discovered.

Retatrutide by goal

Read Retatrutide's profile filtered through specific research goals.

Retatrutide for Fat LossRetatrutide for Recovery

Related Tools

Not medical advice

Information on DoseVault is for educational purposes only and is not a substitute for medical advice, diagnosis, or treatment from a qualified healthcare provider.